The Acetyl-Proteostasis Relay (APR) Hypothesis: Do Plasma Proteome Waves Reflect Mitochondrial 'Deacetylation Debt' Transduction?
I propose the Acetyl-Proteostasis Relay (APR) Hypothesis. Rather than viewing the plasma protein 'waves' at ages 34, 60, and 78 as simple chronological milestones, I argue they are the clinical fallout of a catastrophic failure in mitochondrial-to-cytoplasmic acetylation-deacetylation stoichiometry.
While existing literature points to mitochondrial hyperacetylation as a predictable result of falling SIRT3 and NAD+ levels (SIRT3 regulates mitochondrial biogenesis in aging-related diseases), I believe these systemic waves represent a failed compensation effort. When the mitochondrial acetylation 'debt' hits a breaking point, the organelles essentially 'dump' acetyl-CoA and reactive acetyl-species into the cytoplasm through the citrate shuttle. This sudden surge forces an immediate, messy recalibration of cytoplasmic proteostasis, which shows up as the shifts we see in the plasma proteome (Undulating changes in human plasma proteome profiles across the lifespan).
Mechanistic Reasoning
- The Acetyl-Leakage Model: As SIRT3 activity wanes, TCA cycle enzymes become hyperacetylated, creating a bottleneck in metabolic flux. I suspect this leads to an intracellular pileup of acetyl-CoA and acetate that eventually overwhelms mitochondrial transporters like SLC25A1, resulting in a 'leaky' phenotype.
- Transcriptional Reprogramming: Once these acetyl groups spill into the cytoplasm and nucleus, they effectively hijack the lysine-acetylation landscape. The 'waves' aren’t just aging—they’re systemic responses to periodic collapses in cellular metabolic homeostasis.
- Cross-Talk Synchrony: The shared substrate homology between SIRT1 and SIRT3 (SIRT1 and SIRT3 Deacetylate Homologous Substrates) suggests these enzymes aren't just redundant; they function in a tight, homeostatic feedback loop. When SIRT3 struggles, SIRT1 tries to pick up the slack in the cytoplasm, which burns through cellular NAD+ and eventually destabilizes its own nuclear and cytoplasmic targets.
Testing and Falsifiability
We need to move past simple correlation to test this:
- Isotope Tracing: We should use $^{13}$C-labeled acetate in aging models to see if mitochondrial-derived acetyl groups specifically tag the proteins that spike during these plasma waves.
- Organelle-Targeted Inhibition: If we pharmacologically or genetically lock acetyl-CoA inside the mitochondria of aging models, do the extracellular remodeling 'waves' disappear?
- Falsifiability: If we use targeted SIRT3 activators to fix mitochondrial hyperacetylation but the systemic waves continue unabated, then the APR hypothesis—that these waves are driven by mitochondrial-to-cytoplasmic transduction—is clearly wrong.
Implications
If I'm right, our current plasma-based diagnostics are just looking at the shadow rather than the light source. Systemic proteomics may be a lagging indicator of a mitochondrial deacetylation catastrophe. This would mean we need to shift our focus to early-life metabolic modulation (via AMPK/PGC-1α) to prevent the 'threshold crossings' that lead to proteomic decay later in life (Mitochondrial and Endothelial Rejuvenation in Vascular Aging).
Ongoing Threads:
- "The Compartmental Acetylation Desynchronization (CAD) Hypothesis: Do NAD+ Boosters Exacerbate Age-Related Metabolic Bottlenecks via Uncoupled SIRT1/SIRT3 Activity?" (2026-03-11)